Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PhreesiaPHR +9.54%66 Debt-to-Equity is 0.26 as of Apr. 2026, which is 420% above its 10-year median of 0.05. GuruFocus rates PHR with a GF Score™ of 66/100 and a GF Value™ of $27.14 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 556 Healthcare Providers & Services companies, Phreesia ranks better than 63.31% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Phreesia's Debt-to-Equity or its related term are showing as below:
PHR'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.03 Med: 0.05 Max: 0.31
Current: 0.26
During the past 9 years, the highest Debt-to-Equity Ratio of Phreesia was 0.31. The lowest was -2.03. And the median was 0.05.
PHR's Debt-to-Equity is ranked better than 63.31% of 556
companies
in the Healthcare Providers & Services industry
Industry Median: 0.42
vs PHR: 0.26
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Phreesia Debt-to-Equity Related Terms
Phreesia Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Phreesia's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHR vs MDRX, WEAV, SOPH: Debt-to-Equity Comparison
For the Health Information Services subindustry, Phreesia's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phreesia Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Phreesia's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Phreesia's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phreesia (PHR) has a Debt-to-Equity of 0.26 as of Apr. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Phreesia and its competitors. This is 420% above median its historical median of 0.05. According to the industry distribution chart, Phreesia ranks #204 out of 556 companies in the Healthcare Providers & Services industry, placing it in the top 36.7%.
Is Phreesia's Debt-to-Equity too high?
Phreesia's current Debt-to-Equity of 0.26 is 420% above median its 10-year median of 0.05. The Healthcare Providers & Services industry median Debt-to-Equity is 0.42. Phreesia's value of 0.26 is 38.1% below this industry median. Based on the distribution chart, Phreesia ranks #204 out of 556 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Phreesia has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Phreesia's Debt-to-Equity compare to MDRX and WEAV?
According to the Healthcare Providers & Services industry distribution chart, Phreesia ranks #204 out of 556 companies for Debt-to-Equity. This puts Phreesia in the upper half of its industry. The industry median Debt-to-Equity is 0.42. Phreesia's value of 0.26 is 38.1% below this benchmark. While the company's 10-year median is 0.05 vs. the industry median of 0.42, Phreesia has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 556 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phreesia's current Debt-to-Equity of 0.26 is 38.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Phreesia and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phreesia's current Debt-to-Equity is 0.26, which is 420% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phreesia stock overvalued right now?
Based on GuruFocus' analysis, Phreesia (PHR) is currently considered Possible Value Trap. The stock's GF Value™ is $27.14, compared to a current price of $12.51 — trading 53.9% below its estimated fair value. The current Debt-to-Equity is 0.26, which is 420% above median its 10-year median of 0.05 and 38.1% below the Healthcare Providers & Services industry median of 0.42. Phreesia's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Phreesia (PHR), the current Debt-to-Equity is 0.26 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phreesia (PHR) Overvalued in 2026?
Based on GuruFocus' analysis, Phreesia stock appears to be undervalued.
The current stock price of $12.51 is trading 53.9% below its estimated GF Value™ of $27.14.
GuruFocus considers Phreesia to be Possible Value Trap.
Key valuation signals for PHR:
Debt-to-Equity: 0.26 (420% above median its 10-year median of 0.05)
GF Value™: $27.14 vs. price of $12.51 (53.9% below fair value)
Industry Position: 38.1% below the Healthcare Providers & Services median (#204 of 556)
No single metric tells the full story. See the PHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phreesia Inc is a provides an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions, enabling healthcare organizations to activate patients, streamline administrative processes, and improve financial performance across the care continuum. The group serves a diverse group of healthcare organizations, including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest, and not-for-profit and other organizations.
66GF Score
Get the complete analysis for PHR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHR has been successfully added to your 
